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Background: Influenza virus is responsible for annual deaths due to seasonal epidemics and is the cause of major
pandemics which have claimed millions of human lives over the last century. Knowledge about respiratory virus
transmission is advancing. Spread is likely through the air, but much work remains to be done to characterize the
aerosols produced by infected individuals, including viral particle survival and infectivity. Although coughs have
been characterized, little work has been done to examine coughs from infected individuals. The WeCoF project
aims at providing evidence to support prevention measures to mitigate person-to-person influenza transmission in
critical locations, such as hospitals, and during pandemics.
Findings: A novel experimental cough chamber facility – the FLUGIE – has been developed to study the far-field
aerodynamics and aerosol transport of droplets produced by the coughs from humans naturally-infected with
influenza. The flow field of each cough is measured using Particle Image Velocimetry (PIV). A preliminary study
involving 12 healthy individuals has been carried out in order to quantify the strengths of their coughs at a distance
of 1 m from the mouth. The spatially averaged maximum velocity was determined and the average value was
0.41 m/s across 27 coughs of good data quality. The peak value of velocity was also extracted and compared with
the average velocity.
Conclusions: Preliminary results show that there is significant air motion associated with a cough (on the order of
0.5 m/s) as far away as 1 m from the mouth of the healthy person who coughs. The results from this pilot study
provide the framework for a more extensive participant recruitment campaign that will encompass a statistically-
significant cohort.
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Introduction
We have gained extraordinarily detailed knowledge in the
past decade about the molecular nature of influenza virus
and other respiratory viruses yet surprisingly little is
known about how respiratory viruses are transmitted from
person to person. Mathematical modelling of households,
containing infected individuals, showed aerosol transmis-
sion to be more significant than contact transmission for
influenza virus and that airborne transmission may be a
significant contributor [1,2]. Recent reviews of the litera-
ture support this important possibility [3,4].* Correspondence: wlin26@uwo.ca
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unless otherwise stated.Aerosols consist of particles in a range of sizes. Trad-
itionally droplets of >5 μm diameter have been implicated
in short range (<1 m) spread, and droplet nuclei of <5 μm
are believed to be responsible for longer range or airborne
transmission (>1 m) [5]. However, larger-sized particles
may be responsible for wider pathogen spread depending
on other factors. For example, particles of the same size
may travel different distances, depending on the velocity
of the jet propelling them [6]. These particle dynamics re-
main undefined in the clinical setting, and the implications
are significant from an infection prevention and control
perspective. In addition to its effect on dispersion, particle
size has implications for the inhaling host. Larger particles
(>10 μm) will be deposited by impaction in the upper
respiratory tract and smaller particles (0.003-5 μm) may
penetrate the tracheobronchial and alveolar regions,Ltd. This is an Open Access article distributed under the terms of the Creative
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studying the aerosols produced by infected individuals, we
hope to precisely characterize how long virus infectivity
persists in suspended aerosol droplets of various sizes. Re-
cent work has begun to address this question for bacterial
transmission by patients with cystic fibrosis [8,9]. The
question of droplet survival duration pertains to droplet
size distribution and, on this front, there are discrepancies
across the literature which are likely due to the varying
measurement methodologies and techniques. Solid impac-
tion with micrometry, a method that is insensitive to
smaller droplets, revealed particle sizes from 1 to 2,000 μm
[10]. Size distribution analysis using an optical droplet
counter [11-13] is reportedly less accurate for particles
>2 μm [14] but is useful in the submicron size range.
Other previous techniques to measure size distribution in-
clude aerodynamic droplet sizer [15,16], scanning mobility
particle spectrometer [15], Andersen six-stage cascade im-
pactor [17], electrical low pressure impactor [18], inter-
ferometric Mie imaging [19] and laser diffraction [13,20].
Aside from the dependency on initial size, the change in
droplet size due to evaporation and condensation is also
directly related to their chemical composition [21]. Recent
findings suggest a tri-modal size distribution during speech
or voluntary coughing, with bronchiolar fluid film burst
and laryngeal modes both contributing to a distribution
peak centred near 1 μm size and with an oral mode yield-
ing a distribution peak centred near 100 μm size due to
droplets produced between the epiglottis and the lips [22].
Measurements near the mouth (0.17 m distance) of
healthy non-smokers, giving best-effort voluntary coughs,
indicate that 99% of expelled droplets are inhalable
(<10 μm) [20]. For infected individuals, significant influ-
enza RNA also appears to be contained in droplets with
diameters in the respirable size range - 35% of influenza
RNA was found in droplets of greater than 4 μm diameter,
23% in droplets of 1 to 4 μm diameter and 42% in droplets
of less than 1 μm diameter [23] - and symptomatic sub-
jects appear to emit more particles [18]. However, few re-
sults are available for the relationship between droplet size
and infectivity for influenza virus.
The viability of airborne pathogens also depends on other
factors, including environmental humidity, temperature
and the presence of ultraviolet light. The relationship be-
tween these factors and infectivity is poorly understood. A
recent study using a breathing mannequin and bioaerosol
samplers indicated that high relative humidity (RH) was
associated with reduced infectivity of influenza virus [24].
Earlier studies using small settling chambers, influenza
bioaerosols and guinea pigs found inactivation at high RH
[25-28]. Evaporation and particle shrinkage are expected
since particles typically enter an environment at lower RH
than the respiratory tract [14]. The evaporation process is
fast; particles of 10 mm diameter or less typically evaporatein less than 0.5 seconds [21]. At low RH, droplets evaporate
more quickly and remain suspended longer compared to
droplets generated under conditions of higher RH, thereby
increasing the probability of ensuing inhalation [6,21,29].
Temperature has also been shown to enhance or interrupt
transmission at low (5°C) or high (30°C) temperature, re-
spectively, for all values of RH [28]. Assessment of data in
the literature suggested a relationship between absolute hu-
midity (AH) and influenza survival. When extended to a
human population level study, negative local daily deviation
of AH from its 31 year mean was found to be associated
with the start of influenza outbreaks during the winter
[30,31]. Studies on the effect of ultraviolet light irradiation
showed avian influenza A (H7N9) virus was inactivated
after at least thirty minutes of exposure [32], while adenovi-
ruses appeared to be UV-resistant [33,34]. The vaccinia
virus was found to be less susceptible to ultraviolet radi-
ation at high RH than at low RH [35]. The precise mecha-
nisms through which RH, AH, temperature and UV light
exposure affect virus transmission and survival require
clarification.
Since the Severe Acute Respiratory Syndrome corona-
virus (SARS CoV) outbreak in 2003 [36], the scientific and
medical communities, as well as the general public, have
gained an appreciation of the public health importance of
understanding respiratory virus transmission. Although
cough droplet sizes have been characterized, more research
is needed to examine cough flows from infected individ-
uals. Much is known about airflow rates during coughing
[37-39], including parameters such as Cough Peak Flow
Rate (CPFR), Peak Velocity Time (PVT) and Cough Ex-
pired Volume (CEV), that is the area under the flow rate
versus time curve. A study of 12 female and 13 male sub-
jects showed that the non-dimensional airflow rate (Flow
rate/CPFR) versus non-dimensional time (Time/PVT)
curve could be defined by two gamma-probability func-
tions based on the medical parameters of CPFR, PVT
and CEV that were themselves related to height, weight
and gender [40]. Also, a sequential cough was found to
be a combination of two single coughs, with the first be-
ing approximately the same as a single cough, whilst the
second was a scaled down version of the first. Visualiza-
tions [40] showed that the airflow direction did not vary
greatly amongst the subjects and, although mouth
opening remained constant during a cough, there was a
considerable variation of area across the subjects with
no correlation to other parameters such as height. Their
research examined the bulk parameter of flow rate,
whilst earlier studies examined the flow field qualita-
tively using strobe photography [41] or thermal plume
imaging by Schlieren [42]. More recently, quantitative
analysis of shadowgraph images indicated that this tech-
nique requires a significant temperature difference (10°C)
between exhaled air and room temperature and that
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0.6 m from the source [43]. Quantitative analysis of high-
speed video images of a cough were limited to a similar
range whilst also requiring the cougher to expel cigarette
smoke as a tracer substance [44], which is problematic to
apply in the study of humans with respiratory illness due
to the unacceptable possibility of causing harm to partici-
pants. Accurate velocity measurements at greater distances
in the far-field of a cough require a different measurement
technique and approach.
Particle Image Velocimetry (PIV) velocity measurements
have been undertaken using an artificial cough flow simu-
lator [45,46], a thermal mannequin with simulated breath-
ing [47,48] and healthy human subjects [19,49-51]. Such
measurements have revealed a peak cough velocity of 6 to
22 m/s, with an average of 11.2 m/s [51], but usually
mouth area is merely assumed and not measured [50-52].
Kwon et al. [53] reported average initial cough velocities
of 15.2 m/s (males) and 10.6 m/s (females), with the angle
of exhaled air being 38° (males) and 32° (females), al-
though it is doubtful whether this difference in angle is
statistically significant. Singh et al. [39] found the peak
flow rate produced by women to be 60% that of men and
Chao et al. [19] reported the maximum cough velocity of
women to be approximately 77% that of men. On the
other hand, VanSciver et al. [49] found no significant dif-
ference in maximum cough velocity related to sex and
weight of the cougher. Furthermore, they noted that, from
the fluid dynamic point of view, a cough may be consid-
ered as a short-duration transient jet, being notably unlike
a very-short-duration jet in which much of the cough
would be entrained in a single vortex ring. Their PIV data
showed a wide range of maximum cough velocities (1.5 to
28.8 m/s) and that the self-similarity of flow profiles asso-
ciated with a transient jet was not applicable to coughs,
such that it is necessary to develop an envelope of cough
profiles rather than attempting to define a “typical” cough.
The measurements by Zhu et al. [51] showed that some
saliva droplets produced during a cough can travel further
than 2 m and (using the Lagrangian equation) that the
transport characteristics of expelled saliva droplets change
with size. Furthermore, a recent study of patients with cys-
tic fibrosis emitting cough aerosols, which were collected
with an Anderson Impactor in a wind tunnel of modest
cross-sectional area, reported that viable bacteria can
travel 4 m from the patient or remain aloft for up to 45 mi-
nutes [9]. These findings call into question the “3 feet/1
metre rule” or “6 feet/2 metre rule”, which have been con-
sidered to be safe separation distances for preventing
droplet transmission [54], and motivate further study
of virus-laden bioaerosols and the velocity field at ex-
tended distances from the source. Indeed, all previous
PIV flow measurements have been taken near the
mouth, where velocities are highest, rather than fardownstream near the limits of possible person-to-
person transmission.
The novelty of the current collaborative research pro-
ject – the Western Cold and Flu (WeCoF) aerosol study -
lies in the fact that the fluid dynamics of the jet aerosols
produced by a minimally-confined cough is being exam-
ined concurrently with the biological processes associated
with virus droplet formation and transmission, using hu-
man subjects when they are naturally infected by influenza
virus and, again, when they return to health. This is in
contrast to previous fluid dynamic studies that have mea-
sured the velocity field using artificial aerosol sources or
only healthy subjects. Ultimately, the research aims of the
present WeCoF project are;
1. to understand the penetration of viral droplets into
the ambient environment,
2. to rigorously test the “3 feet/1 metre” and “6 feet/2
metre” rules and
3. to identify host determinants of individuals who
emit higher quantities of virus which disperse
further,
all of which are important for implementation of fu-
ture transmission prevention measures. The measured
data will also be of use to other researchers who are
attempting to develop realistic theoretical [55] or com-
putational fluid dynamics (CFD) [50,56] models for
cough jets/plumes and virus transmission. Such models
require reliable modeling of the transport of aerosol
droplets and virus particles. In addition, data from hu-
man subjects may be used to test simpler models that
use the spatial distribution of expiratory aerosols and the
viability functions of airborne viruses to estimate expo-
sures to airborne viruses in the indoor environment,
where previously such models were based on artificial
puff sources, e.g. [57]. This introductory review has cov-
ered issues such as cough droplet sizes and the influence
of environmental parameters, notably temperature and
relative humidity, which will be studied as part of the
WeCoF project. However, the present paper focuses on
the experimental facility and methods and presents the
results from the initial experiments using healthy human
volunteer subjects.
Test facility
A novel experimental facility (the FLUGIE cough cham-
ber) has been constructed at Western and protocols devel-
oped for its use. Biosafety and research ethics approvals
have been obtained for studies involving human partici-
pants who are naturally-infected with pathogens such as
influenza virus. Figure 1 shows a diagrammatic layout of
the facility for PIV measurements, with the subject seated
outside the chamber. Since the entrainment of ambient air


























Figure 1 Diagrammatic layout of the 2 m × 2 m × 2 m FLUGIE
cough chamber (all dimensions shown in metres).
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jet, a solid barrier with only a small opening for the mouth
(such as the 5 × 3 cm hole used by [51]) is inappropriate.
In the FLUGIE, the opening is pear-shaped such that the
participant’s nose and mouth area are unobstructed whilst
a cough is directed into the enclosed test chamber. The
major vertical axis of the pear-shaped opening is 15 cm
high and the base of the opening, where the participant’s
chin rests, is 67 cm above the chamber floor. The minor
horizontal axis of the pear-shaped opening is 10.5 cm
wide. This chamber inlet has a cover, which is only opened
when a cough is introduced into the chamber.
The position of the participant’s head is fixed by a chin
rest and a forehead rest, such that the angle of the cough
is horizontal and consistent over multiple trials. Although
it may be argued that a more natural cough would be ob-
served by permitting unrestricted head motion, it is likely
that such freedom would permit a significant cough vel-
ocity component due to forward translation of the partici-
pant’s upper body during the expulsive phase, as well as
introduce a greater unpredictability to the cough flow tra-
jectory, which would be problematic for any experimental
technique with a limited measurement site or window.
From the perspective of achieving the present research
aims in a controlled laboratory experiment, it is acceptable
to examine the cough velocity produced by pulmonary
effort alone.
An open bench set-up [20] may be distinguished from a
study of a confined cough but, in essence, all coughs in an
indoor setting are the latter type. The salient point is to
allow sufficient separation between the cough and all solid
boundaries, such that the flow does not exhibit any signifi-
cant deviation from a cough in fully open surroundings.Even though a participant may be coughing at an open
bench towards an open fume hood, the distance from the
mouth to the fume hood is of interest, as well as whether
the fume hood fan is operating and possibly affecting the
cough flow. Hence, a chamber of ample size is preferable
as a quiescent environment in which a cough flow may be
studied without flow disturbances from uncontrolled
surroundings. The internal dimensions (1.81 m length,
1.78 m width and 1.81 m height) for FLUGIE were sized
for separation distances to be greater than participant
mouth diameter by more than an order of magnitude. At
the measurement window, the separations decrease to less
than an order of magnitude due to the lateral spreading of
the cough flow with distance from the mouth, yet remain
several times the lateral extent of the cough. The test
chamber is raised by 0.25 m above the laboratory floor
and mounted upon casters to allow measurement at vari-
ous streamwise positions.
In order to quantify the viral content of the aerosols
produced during coughs, particles are sampled by collec-
tion onto polytetrafluoroethylene (PTFE) membrane fil-
ters of 1.0 μm pore size and 37 mm diameter. As shown
by Figure 2, a filter and cellulose support pad is held be-
tween a clear styrene cassette ring and bottom. The
open-faced cassettes are suspended from the chamber
roof, on the chamber centreline, at two distances from
the cough inlet (0.5 m and 1.0 m). The constant-flow air
sampling pumps (SKC Inc., Airchek 224-PCXR3) are op-
erated at a flow rate of 4000 ± 40 mL/min. Expelled
pathogens are collected upon the membranes with the
assistance of the air flow samplers.
The identity of the pathogen acquired by each study par-
ticipant is confirmed by asking for a self-collected mid-
turbinate swab (MTS) and these specimens are interrogated
by multiplex polymerase chain reaction (multiplex-PCR)
assay for a panel of respiratory viruses (RVP Fast, Luminex).
The viral content from the membranes is quantified using a
virus-specific monoplex quantitative real-time PCR assay
and calculated using quantitative curves and number of li-
tres of air sampled.
Methods
Particle Image Velocimetry of coughs
Separate measurements are performed to quantify the
cough flow field. Optical access areas into the test cham-
ber are outlined in light blue in Figure 1. A beam of
green light (532 nm wavelength) horizontally emitted
from the laser head (120 mJ, Nd:YAG crystal) is re-
directed to vertical by a 45°-angled mirror and expanded
into a narrow light sheet (~1 mm thickness) with cylin-
drical and spherical lenses. The light sheet enters the
test chamber through a glass window in its floor, and il-
luminates a centreline plane from the test chamber floor
to the test chamber roof. The Vieworks VA-4 M32
Figure 2 Diagram of the bioaerosol sampling cassette assembly (top), photograph of a cassette attached to a sampling pump (centre)
and photograph of the cassettes in operation in the cough chamber (bottom).
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lution of 10.0 pixels per mm and a sensor array of
1,752 pixels by 2,336 pixels, where the longer side is ori-
ented vertically for this experiment. The camera is fo-
cused upon the light sheet at the chamber centreline
and optical access is through a glass window on a cham-
ber wall.
The test chamber is seeded with titanium dioxide par-
ticles (rutile mineral form). The product specifications
indicate a particle size distribution ranging from 0.15 to
0.47 μm, where 69% of the particles are in the 0.34 to
0.43 μm size bin and 29% of the particles are in the 0.27
to 0.34 μm size bin. The titanium dioxide (TiO2) powder
is dried in a vacuum-oven, stored in a vacuum container
to minimize clumping and aerosolized using a custom-
crafted version of the Pitt 3 aerosol generator [58]. This
device consists of a cylindrical drum with small inlet and
outlet ports near its bottom and top ends, respectively.
The drum is filled with TiO2 powder, which is carried up
and out of the drum by the flow driven by a 30 kPa air
line attached to the inlet port. The drum is placed on
top of a loudspeaker, which generates sound waves to vi-
brate and break up the powder. From the outlet port of
the aerosol generator, the aerosolized particles enter a
settling chamber mounted on top of the test chamber
through a tube with perforations. The FLUGIE settling
and test chambers are separated by a fine mesh, which
permits TiO2 particles, under the action of gravity and
local airflow, to gently enter the test chamber along its
centreline. The cough jet generated by the participantFigure 3 Field of view for the cough airflow measurements (left) and
cough (right).disturbs the TiO2 particles which are imaged to obtain
quantitative information of the flow field.
Thus, this setup achieves an intersection of the tracer
particles, the light sheet illuminating the tracer particles,
the focused field-of-view of the camera recording the illu-
minated tracer particles and the cough flow, over a sizable
region of space and time (400 cm2 and 5 s, respectively). A
pulse generator (Berkeley Nucleonics Corporation, Model
555-4C) is used to control the timing and synchronizing
of the laser and camera. Image pairs are captured at a rate
of 16.7 Hz, from which instantaneous velocity fields are
calculated using commercial software (TSI Incorporated,
Insight3G) that cross-correlates the image pairs. In the
tests reported here the field-of-view of the camera is
centred at 1.00 m from the cough inlet. For each study
participant, following the aforementioned cough droplet
sampling, PIV is performed for another three independent
single coughs with a settling time of 30 s between each
cough.
A preliminary study involving healthy individuals has
been carried out in order to assess the performance of
PIV for measuring the far-field region of this transient
and turbulent air flow. In addition, this work has pro-
vided the framework for a more extensive campaign that
will encompass a statistically significant cohort. The vel-
ocity fields associated with the coughs from 12 healthy
young adults were quantified at a distance of 1 m away
from the mouth. This limited study with healthy volun-
teers leads into the recruitment and study of individuals


















Velocity history of three coughs from participant F1
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Velocity history of three coughs from participant M1
Cough #1, Spatial max
Cough #1, Spatial mean
Cough #2, Spatial max
Cough #2, Spatial mean
Cough #3, Spatial max


















Velocity history of three coughs from participant M2
Cough #1, Spatial max
Cough #1, Spatial mean
Cough #2, Spatial max
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Cough #3, Spatial mean
Figure 4 Time-histories of three coughs from a female (F1) and
two male (M1 and M2) participants.
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The University of Western Ontario Research Ethics
Board for Health Sciences Research Involving Human
Subjects (HSREB) reviewed and approved this study.
The HSREB is registered with the U.S. Department of
Health & Human Services under the registration num-
ber IRB 00000940.
Participant recruitment
In an ongoing pilot study at a university student health
clinic (Student Health Services at Western University), a
small cohort of undergraduate students, who were
naturally-infected with influenza, are being referred by
clinicians to the WeCoF aerosol study. Written informed
consent is being obtained from all participants in this
ongoing study. The HSREB reviewed and approved this
study.
Disinfection measures
A germicidal lamp, which produces continuous light in
the Ultra-Violet B range, is used to disinfect the test
chamber between study participants. In addition, an out-
let has been retrofitted with a HEPA filter through which
chamber air can be withdrawn to further reduce the risk
of viral contamination between subjects. The experi-
ments are repeated several weeks later, with the same
participants, after recovery from the respiratory illness
to permit an assessment of the differences in the coughs
between an infected and a healthy person.
Discussion of preliminary results
Preliminary experiments have been carried out involving
12 healthy volunteer participants (9 male, 3 female, ages
20 to 32). Since they were healthy, cough airflow mea-
surements using PIV were conducted without viral aero-
sol sampling. Each participant produced 3 coughs with
the PIV system recording image pairs prior to, during
and after the cough. These were then processed to yield
instantaneous velocity vector arrays within the field of
view. Figure 3 (left) shows that the field of view was lo-
cated 1.00 m downstream of the entry to the FLUGIE
cough chamber and encompassed a region of 174.8 mm
in the streamwise direction, centred at the 1.00 m loca-
tion. The field of view extended over 233.1 mm vertically
and was below the level of the cough to take into ac-
count the fact that, even if the cough was initially di-
rected horizontally forward by the study participant,
most of the coughs had drifted downwards at the 1 m
location, contradicting the importance of buoyancy in a
proposed model based on visualizations out to 0.70 m
from a participant in an open laboratory setting [55]. An
example of a processed vector field is shown in Figure 3
(right), where the green arrows are vectors that have
passed validation by the Insight3G processing software.Red vectors are spurious values, which were typically
attributable to the reduced light sheet intensity at the
edges of the field-of-view, whose size approached the
upper limits of this PIV equipment. Based on the se-
lected interrogation window size (i.e. the area from
which a vector was calculated), the maximum possible
number of vectors in each processed image was 3,816.
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coughs recorded on different days. For 3 participants,
the results were poor due to low particle seeding levels
and low numbers of validated velocity vectors (only
about 0.8% of the total number of vectors were consid-
ered to be accurate, representing approximately 30 vec-
tors per image). Three other participants were recorded
in another session and showed the best results in terms
of percentage of validated vectors, with values aroundTable 1 Summary of 36 measured coughs from 12 healthy pa




































M9 3 0.23190% (their data are shown in Figure 4). The other 6 sub-
jects were recorded on a separate day and showed ac-
ceptable validation levels in the 70 to 80% range. The
findings for each of the three coughs by each of the
twelve participants are given in Table 1, where the first
character in the participant identifier (ID) indicates par-
ticipant gender (F for female and M for male) and the
second character is an integer index for each individual
of that gender. The magnitude of each vector in eachrticipants
Mean # of Valid vectors (%) Observations
89.5 Strong; wide; partially high
90.5 Strong; wide
91.3 Partially high
84.6 In field of view
81.8 Missed, too low
81.8 In field of view then low
74.2 Strong; wide
74.9 Strong; in field of view
74.3 Strong; horizontal flow
90.2 Strong; partially high
90.2 Weak; wide; multiple jets
90.0 In field of view; intermittent
91.2 In field of view
90.7 Low
90.1 Strong; wide
79.0 Sharp front; wide
77.5 Violent; wide
76.7 Sharp front; wide; intermittent
0.8 Low seeding; spurious vectors
0.7 Low seeding; spurious vectors
0.7 Low seeding; spurious vectors
0.7 Low seeding; spurious vectors
0.7 Low seeding; spurious vectors
0.7 Low seeding; spurious vectors
73.2 Strong; wide
72.2 Wide; some spurious vectors
71.8 Turbulent; in field of view
0.7 Low seeding; spurious vectors
0.7 Low seeding; spurious vectors
0.8 Low seeding; spurious vectors
74.3 Weak; partially low
72.1 Weak; partially low
73.3 Best for M8; intermittent
74.7 Very weak and low
75.9 Weak; partially low
74.1 Strong; wide
Figure 6 Example of the decay of cough front velocity with
distance from mouth.
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(i.e. spatially) over the entire number of such validated
vectors to produce a value representing the average air
velocity within the field of view and the maximum
mean value, occurring in each individual cough event,
is shown in Table 1. A representative measure of proc-
essed data quality is included, together with observa-
tions. Furthermore, the peak value of velocity from
each image pair was extracted and plotted against time
for that cough.
The time-histories of spatially-averaged and peak vel-
ocity values for three subjects are shown in Figure 4. It
may be seen that, in all cases, the motion of the cough
through the field of view, located a metre away from the
cougher, is clearly defined with an initial rapid increase
of velocity followed by a slower decay. It is also evident
that there is no single characteristic shape for a cough
velocity profile and, thus, it is necessary to define an en-
velope of cough profiles based on the measurement and
analysis of a larger number of coughs than those exam-
ined in these initial trials.
As would be expected from the limitation on the PIV
window size and the variable physical traits of study par-
ticipants, it was found that there was considerable vari-
ation in location and strength of each cough, with some
coughs missing most of the imaged field of view entirely.
The distribution of values of the spatially-averaged max-
imum velocity magnitude is illustrated in Figure 5. The
average value across all 36 coughs is 0.52 m/s, but with
the data from the three poor quality experiments removed,
the average across the remaining 27 tests is 0.41 m/s.
These values indicate that there is significant air motion
during a cough, of the order of 0.5 m/s, at a location as far
away as 1 m from the person who is coughing. During the
set-up phase for this preliminary study, a single volunteer
produced 5 coughs, with a 180-mm-wide PIV field being




























Figure 5 Variability of maximum spatially-averaged velocity
magnitude across the 36 trials.cough. The participant attempted to produce a series of
coughs each of the same strength. Although the quality of
the resulting vector field was not sufficient to provide
quantitative data, it was possible to identify the arrival of
the cough front at each location and, thereby, estimate the
velocity of the cough front at the centre of each field of
view. The results are shown in Figure 6, illustrating the
rapid decrease in velocity in the near-field of the mouth,
as would be expected. At 1 m from the mouth the cough
front velocity has a magnitude in agreement with the aver-
age of the spatially-averaged maximum velocity magnitude
from our preliminary study with 12 healthy participants.
Note that the fitted curve is based on an approximation of
a linear growth of the cough jet diameter with distance
from the mouth.
Conclusions
A novel experimental facility – the FLUGIE – has been
designed to study the far-field aerodynamics of human
coughs produced by subjects naturally-infected with re-
spiratory viruses, together with measurement of the
viral content of the droplets produced by those coughs,
in order to quantify the factors relating to person-to-
person airborne transmission of virus. A preliminary
study involving 12 healthy individuals has been carried
out in order to quantify the strengths of their coughs at
a distance of 1 m away from the mouth. The velocity
fields were measured using Particle Image Velocimetry
and the results indicate an important finding, namely
that there is significant air motion during a cough, of
the order of 0.5 m/s, even at a location as far away as
1 m from the person who is coughing.
Competing interests
The authors declare that they have no competing interests.
Savory et al. BMC Research Notes 2014, 7:563 Page 10 of 11
http://www.biomedcentral.com/1756-0500/7/563Authors’ contributions
ES, SM and JS conceived of the WeCoF study and overall methodology and
arranged the funding and required ethics and safety approvals. WEL
designed the facility with technical advice from JS and ES. Data were
acquired by WEL, KB and MCR. ES guided the data analysis by WEL and MCR.
ES interpreted the results and drafted the technical note with assistance
from SM and LRC for the literature review and WEL for technical
descriptions, figures and tables. SM and WEL critically revised the draft. All
authors read and approved the published version and agreed to be
accountable for the accuracy and integrity of the entire work.Acknowledgements
The facility development and preliminary study were funded by the Ontario
Thoracic Society and the Workplace Safety and Insurance Board. Thanks
are due to University Machine Services at Western for the construction of
the FLUGIE facility and to the 12 anonymous experimental participants.
Dr. Sydney Siu provided key assistance with the medical research ethics and
safety approvals. The PIV system was kindly made available by Dr. Kamran
Siddiqui. Dr. Qiuquan (Charles) Guo provided physical assistance in the
laboratory and autoclave training.
Author details
1Department of Mechanical & Materials Engineering, The University of
Western Ontario, 1151 Richmond Street North, London N6A 5B9, Canada.
2Division of Occupational and Environmental Health, Dalla Lana School of
Public Health, University of Toronto, 223 College Street, Toronto M5T 1R4,
Canada. 3Department of Biological Sciences, Sunnybrook Research Institute,
2075 Bayview Avenue, Toronto M4N 3M5, Canada.
Received: 8 March 2014 Accepted: 18 August 2014
Published: 23 August 2014References
1. Atkinson MP, Wein LM: Quantifying the routes of transmission for
pandemic influenza. Bull Math Biol 2008, 70:820–867.
2. Cowling BJ, Ip DKM, Fang VJ, Suntarattiwong P, Olsen SJ, Levy J, Uyeki TM,
Leung GM, Malik Peiris JS, Chotpitayasunondh T, Nishiura H, Simmerman
JM: Aerosol transmission is an important mode of influenza A virus
spread. Nat Commun 2013, 4:1935.
3. Tellier R: Aerosol transmission of influenza A virus: a review of new
studies. J R Soc Interface 2009, 6:S783–S790.
4. Aliabadi AA, Rogak SN, Bartlett KH, Green SI: Preventing airborne disease
transmission: review of methods for ventilation design in health care
facilities. Adv Prev Med 2011, 124064:1–21. doi:10.4061/2011/124064.
5. Siegel JD, Rhinehart E, Jackson M, Chiarello L: 2007 guideline for isolation
precautions: Preventing transmission of infectious agents in health care
settings. Am J Infect Control 2007, 35:S65–S164.
6. Xie X, Li Y, Chwang AT, Ho PL, Seto WH: How far droplets can move in
indoor environments-revisiting the Wells evaporation-falling curve.
Indoor Air 2007, 17:211–225.
7. Canadian Centre for Occupational Health and Safety. http://www.ccohs.
ca/oshanswers/chemicals/how_do.html.
8. Wainwright CE, France MW, O’Rourke P, Anuj S, Kidd TJ, Nissen MD, Sloots
TP, Coulter C, Ristovski Z, Hargreaves M, Rose BR, Harbour C, Bell SC,
Fennelly KP: Cough-generated aerosols of Pseudomonas aeruginosa and
other Gram-negative bacteria from patients with cystic fibrosis. Thorax
2009, 64:926–931.
9. Knibbs LD, Johnson GR, Kidd TJ, Cheney J, Grimwood K, Kattenbelt JA,
O'Rourke PK, Ramsay KA, Sly PD, Wainwright CE, Wood ME, Morawska L, Bell
SC: Viability of Pseudomonas aeruginosa in cough aerosols generated by
persons with cystic fibrosis. Thorax 2014, 69:740–745.
10. Duguid JP: The size and the duration of air-carriage of respiratory droplet
and droplet-nuclei. J Hyg (Lond) 1946, 54:471–479.
11. Fairchild CI, Stampfer JF: Particle concentration in exhaled breath. Am Ind
Hyg Assoc J 1987, 48:948–949.
12. Papineni RS, Rosenthal FS: The size distribution of droplets in the exhaled
breath of healthy human subjects. J Aerosol Med 1997, 10:105–116.
13. Edwards DA, Man JC, Brand P, Katstra JP, Sommerer K, Stone HA, Nardell E,
Scheuch G: Inhaling to mitigate exhaled bioaerosols. Proc Natl Acad Sci U S A
2004, 101:17383–17388.14. Nicas M, Nazaroff W, Hubbard A: Toward understanding the risk of
secondary airborne infection: Emission of respirable pathogens. J Occup
Environ Hyg 2005, 2:143–154.
15. Yang S, Lee GWM, Chen CM, Wu CC, Yu KP: The size and concentration of
droplets generated by coughing in human subjects. J Aerosol Med 2007,
20:484–494.
16. Morawska L, Johnson GR, Ristovski ZD, Hargreaves M, Mengersen K, Corbett
S, Chao CYH, Li Y, Katoshevski D: Size distribution and sites of origins of
droplets expelled from the human respiratory tract during expiratory
activities. J Aerosol Sci 2009, 40:256–269.
17. Fennelly KP, Martyny JW, Fulton KE, Orme IM, Cave DM, Heifets LB: Cough
generated aerosols of Mycobacterium tuberculosis: A new method to
study infectiousness. Am J Respir Crit Care Med 2004, 169:604–609.
18. Hersen G, Moularat S, Robine E, Gehin E, Corbet S, Vabret A, Freymuth F:
Impact of health on particle size of exhaled respiratory aerosols:
Case– control study. CLEAN – Soil, Air, Water 2008, 36:572–577.
19. Chao CYH, Wan MP, Morawska L, Johnson GR, Ristovski ZD, Hargreaves M,
Mengersen K, Corbett S, Li Y, Xie X, Katoshevski D: Characterization of
expiration air jets and droplet size distributions immediately at the
mouth opening. J Aerosol Sci 2009, 40:122–133.
20. Zayas G, Chiang MC, Wong E, MacDonald F, Lange CF, Senthilselvan A, King
M: Cough aerosol in healthy participants: fundamental knowledge to
optimize droplet-spread infectious respiratory disease management.
BMC Pulm Med 2012, 12:11.
21. Redrow J, Mao S, Celik IJ, Posada A, Feng Z: Modeling the evaporation and
dispersion of airborne sputum droplets expelled from a human cough.
Build Environ 2011, 46:2042–2051.
22. Johnson GR, Morawska L, Ristovski ZD, Hargreaves M, Mengersen K, Chao
CYH, Wan MP, Li Y, Xie X, Katoshevski D, Corbett S: Modality of human
expired aerosol size distributions. J Aerosol Sci 2011, 42:839–851.
23. Lindsley WG, Blachere FM, Thewlis RE, Vishnu A, Davis KA, Cao G, Palmer JE, Clark
KE, Fisher MA, Khakoo R, Beezhold DH: Measurements of airborne influenza
virus in aerosol particles from human coughs. PLoS One 2010, 5:e15100.
24. Noti JD, Blachere FM, McMillen CM, Lindsley WG, Kashon ML, Slaughter DR,
Beezhold DH: High humidity leads to loss of infectious influenza virus
from simulated coughs. PLoS One 2013, 8:e57485.
25. Hemmes JH, Winkler KC, Kool SM: Virus survival as a seasonal factor in
influenza and poliomyelitis. Nature 1960, 188:430–431.
26. Schaffer FL, Soergel ME, Straube DC: Survival of airborne influenza virus:
effects of propagating host, relative humidity, and composition of spray
fluids. Archives of Virology 1976, 51:263–273.
27. Steel J, Palese P, Lowen AC: Transmission of a 2009 pandemic influenza
virus shows a sensitivity to temperature and humidity similar to that of
an H3N2 seasonal strain. J Virol 2011, 85:1400.
28. Lowen AC, Mubareka S, Steel J, Palese P: Influenza virus transmission is
dependent on relative humidity and temperature. PLoS Pathog 2007, 3:e151.
29. Aliabadi AA, Rogak SN, Green SI, Bartlett KH: CFD simulation of human
coughs and sneezes: a study in droplet dispersion, heat, and mass
transfer. In Proceedings of ASME International Mechanical Engineering
Congress and Exposition (IMECE 2010): 12–18 November 2010. Vancouver, BC,
Canada: American Society of Mechanical Engineers; 2010:1051–1060.
30. Shaman J, Kohn M, Singer BH: Absolute humidity modulates influenza
survival, transmission, and seasonality. Proc Natl Acad Sci U S A 2009,
106:3243–3248.
31. Shaman J, Pitzer VE, Viboud C, Grenfell BT, Lipsitch M: Absolute humidity
and the seasonal onset of influenza in the continental United States.
PLoS Biol 2010, 8:e1000316.
32. Zou S, Guo J, Gao R, Dong L, Zhou J, Zhang Y, Dong J, Bo H, Qin K, Shu Y:
Inactivation of the novel avian influenza A (H7N9) virus under physical
conditions or chemical agents treatment. Virol J 2013, 10:289.
33. Vonder Haar T, Page M, Marinas B, Shisler J, Boucherie C, Heim V, David F,
Recherche A: A comparative study of the inactivation of adenovirus and
coxsackievirus with ultraviolet light, chlorine, and ozone. In Proceedings of
the Water Quality Technology Conference and Exposition: 14–18 November 2010.
Savannah, GA, USA: American Water Works Association; 2010:2926–2935.
34. Meng QS, Gerba CP: Comparative inactivation of enteric adenoviruses,
poliovirus and coliphages by ultraviolet irradiation. Water Res 1996,
30:2665–2668.
35. McDevitt JJ, Lai KM, Rudnick SN, Houseman EA, First MA, Milton DK:
Characterization of UVC light sensitivity of vaccinia virus. Appl Environ
Microbiol 2007, 73:5760–5766.
Savory et al. BMC Research Notes 2014, 7:563 Page 11 of 11
http://www.biomedcentral.com/1756-0500/7/56336. Campbell A: The SARS Commission - Spring of Fear. In Volumes 2 and 3.
Toronto: Government of Ontario; 2006:1–1204.
37. Leiner GC, Abramowitz S, Small MJ, Stenby VB: Cough peak flow rate.
Am J Med Sci 1966, 251:211–214.
38. Mahajan RP, Singh P, Murty GE, Aitkenhead AR: Relationship between
expired lung volume, peak flow rate and peak velocity time during a
cough manoeuvre. Br J Anaesth 1994, 72:298–301.
39. Singh P, Mahajan RP, Murty GE, Aitkenhead AR: Relationship of peak flow
rate and peak velocity time during voluntary coughing. Br J Anaesth
1995, 74:714–716.
40. Gupta JK, Lin CH, Chen Q: Flow dynamics and characterization of a
cough. Indoor Air 2009, 19:517–525.
41. Jennison MW: Atomizing of mouth and nose secretions into the air as
revealed by high speed photography. In Aerobiology (Publication no. 17).
Edited by Moulton FR. Washington: American Association for the
Advancement of Science; 1942:106–128.
42. Settles GS, Hackett EB, Miller JD, Weinstein LM: Full-scale Schlieren flow
visualization. In Flow Visualization VII. Edited by Crowder JP. New York:
Begell House; 1995:2–13.
43. Tang JW, Nicolle A, Pantelic J, Koh GC, Wang LD, Amin M, Klettner CA,
Cheong DKW, Sekhar C, Tham KW: Airflow dynamics of coughing in
healthy human volunteers by shadowgraph imaging: an aid to aerosol
infection control. PLoS One 2012, 7:e34818.
44. Nishimura H, Sakata S, Kaga A: A new methodology for studying dynamics
of aerosol particles in sneeze and cough using a digital high-vision,
high-speed video system and vector analyses. PLoS One 2013, 8:e80244.
45. Afshari A, Azadi S, Ebeling T, Badeau A, Goldsmith WT, Weber KC, Frazer DG:
Evaluation of cough using Digital Particle Image velocimetry. In
Proceedings of Second Joint EMBS-BMES Conference: 23–26 October 2002.
Houston: IEEE; 2002:975–976.
46. Badeau A, Afshari A, Goldsmith WT, Frazer D: Preliminary predictions of
flow and particulate concentration produced from normal human cough
dispersion. In Proceedings of Second Joint EMBS-BMES Conference: 23–26
October 2002. Houston: IEEE; 2002:246–247.
47. Marr D, Khan T, Glauser M, Higuchi H, Zhang J: On Particle Image
Velocimetry (PIV) measurements in the breathing zone of a thermal
breathing manikin. ASHRAE Trans 2005, 111:299–305.
48. Marr D, Spitzer IM, Glauser MN: Anisotropy in the breathing zone of a
thermal manikin. Exp Fluids 2008, 44:661–673.
49. VanSciver M, Miller S, Hertzberg J: Particle Image Velocimetry of human
cough. Aerosol Sci Technol 2011, 45:415–422.
50. Zhu S, Kato S, Yang JH: Investigation into airborne transport
characteristics of air-flow due to coughing in a stagnant room
environment. ASHRAE Trans 2006, 112:123–133.
51. Zhu S, Kato S, Yang JH: Study on transport characteristics of saliva
droplets produced by coughing in a calm indoor environment. Build
Environ 2006, 41:1691–1702.
52. Zhao B, Zhang Z, Li X: Numerical Study of Transport of droplets or particles
generated by respiratory system indoors. Build Environ 2005, 40:1032–1039.
53. Kwon S-B, Park J, Jang J, Cho Y, Park D-S, Kim C, Bae G-N, Jang A: Study on
the initial velocity distribution of exhaled air from coughing and
speaking. Chemosphere 2012, 87:1260–1264.
54. Kennamer M: Basic infection control for health care providers. 2nd edition.
Albany: Thomson Delmar Learning; 2007:74–78.
55. Bourouiba L, Dehandschoewercker E, Bush JWM: Violent expiratory events:
on coughing and sneezing. J Fluid Mech 2014, 745:537–563.
56. Holmes NS, Morawska L: A review of dispersion modelling and its
application to the dispersion of particles: an overview of different
dispersion models available. Atmos Environ 2006, 40:5902–5928.
57. Sze To GN, Wan MP, Chao CYH, Wei F, Yu SCT, Kwan JKC: A methodology
for estimating airborne virus exposures in indoor environments using
the spatial distribution of expiratory aerosols and virus viability
characteristics. Indoor Air 2008, 18:425–438.
58. Weyel DA, Ellakkani M, Alarie Y, Karol M: An aerosol generator for the
resuspension of cotton dust. Toxicol Appl Pharmacol 1984, 76:544–547.
doi:10.1186/1756-0500-7-563
Cite this article as: Savory et al.: Western Cold and Flu (WeCoF) aerosol
study – preliminary results. BMC Research Notes 2014 7:563.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
